Cargando…

Effects after starting or switching from bisphosphonate to romosozumab or denosumab in Japanese postmenopausal patients

PURPOSE: We aimed to investigate the longitudinal changes in bone metabolic markers and bone mineral density (BMD) after starting or switching from bisphosphonate (BP) to romosozumab (ROMO) or denosumab (DENO) therapies over 12 months and to determine predictors that establish associations with chan...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shimizu, Tomohiro, Arita, Kosuke, Murota, Eihiro, Hiratsuka, Shigeto, Fujita, Ryo, Ishizu, Hotaka, Asano, Tsuyoshi, Takahashi, Daisuke, Takahata, Masahiko, Iwasaki, Norimasa
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Singapore 2021
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8042469/ https://www.ncbi.nlm.nih.gov/pubmed/33847831 http://dx.doi.org/10.1007/s00774-021-01226-1

Ejemplares similares

Short-term efficacy and safety of zoledronate acid or denosumab in Japanese patients with postmenopausal osteoporosis
por: Nakamura, Yumejiro, et al.
Publicado: (2021)

Unintentional Fusion in Preserved Facet Joints without Bone Grafting after Percutaneous Endoscopic Transforaminal Lumbar Interbody Fusion
por: Yamada, Katsuhisa, et al.
Publicado: (2021)

Denosumab versus romosozumab for postmenopausal osteoporosis treatment
por: Kobayakawa, Tomonori, et al.
Publicado: (2021)

Early Clinical Results of Percutaneous Endoscopic Transforaminal Lumbar Interbody Fusion: A New Modified Technique for Treating Degenerative Lumbar Spondylolisthesis
por: Nagahama, Ken, et al.
Publicado: (2018)

Skeletal responses to romosozumab after 12 months of denosumab
por: McClung, Michael R., et al.
Publicado: (2021)

OR13-06 Romosozumab After Denosumab Improves Lumbar Spine Bone Mineral Density And Microarchitecture Greater Than Denosumab Continuation In Postmenopausal Women
por: Hong, Namki, et al.
Publicado: (2023)

Denosumab compared to bisphosphonates to treat postmenopausal osteoporosis: a meta-analysis
por: Wu, Jiaqi, et al.
Publicado: (2018)

Denosumab or Zoledronic Acid in Postmenopausal Women With Osteoporosis Previously Treated With Oral Bisphosphonates
por: Miller, P. D., et al.
Publicado: (2016)

Romosozumab was not effective in preventing multiple spontaneous clinical vertebral fractures after denosumab discontinuation: A case report
por: Kashii, Masafumi, et al.
Publicado: (2020)

The efficacy and safety of denosumab in postmenopausal women with osteoporosis previously treated with bisphosphonates: A review
por: Zhu, Yilin, et al.
Publicado: (2019)

Two Cases of Frontal Variation of Idiopathic Calvarial Thinning—Therapeutic Effect of Denosumab and Romosozumab
por: Baek, Seungjin, et al.
Publicado: (2023)

Predictors of cartilage degeneration in patients with subchondral insufficiency fracture of the femoral head: a retrospective study
por: Shimizu, Tomohiro, et al.
Publicado: (2020)

Medication-taking behaviour in Bulgarian women with postmenopausal osteoporosis treated with denosumab or monthly oral bisphosphonates
por: Petranova, T., et al.
Publicado: (2017)

Comparative effects of denosumab or bisphosphonate treatment on bone mineral density and calcium metabolism in postmenopausal women
por: Augoulea, A., et al.
Publicado: (2017)

Meta-analysis of the effects of denosumab and romosozumab on bone mineral density and turnover markers in patients with osteoporosis
por: Hu, Mingwei, et al.
Publicado: (2023)

Romosozumab for osteoporosis
Publicado: (2021)

Bone mineral density gains with a second 12-month course of romosozumab therapy following placebo or denosumab
por: Kendler, D.L., et al.
Publicado: (2019)

Persistence with denosumab and persistence with oral bisphosphonates for the treatment of postmenopausal osteoporosis: a retrospective, observational study, and a meta-analysis
por: Karlsson, L., et al.
Publicado: (2015)

Future of bisphosphonates and denosumab for men with advanced prostate cancer
por: Iranikhah, Maryam, et al.
Publicado: (2014)

Can denosumab be a substitute, competitor, or complement to bisphosphonates?
por: Kim, Su Young, et al.
Publicado: (2017)

Cost-effectiveness of romosozumab for the treatment of postmenopausal women at very high risk of fracture in Canada
por: Goeree, Ron, et al.
Publicado: (2022)

Romosozumab for the treatment of osteoporosis
por: McClung, Michael R.
Publicado: (2018)

Cost-effectiveness of romosozumab for the treatment of postmenopausal women with severe osteoporosis at high risk of fracture in Sweden
por: Söreskog, E., et al.
Publicado: (2021)

Effect of Romosozumab on Trabecular Bone Score Compared to Anti-Resorptive Agents in Postmenopausal Women with Osteoporosis
por: Jeong, Chaiho, et al.
Publicado: (2021)

Efficacy and Safety of Romosozumab Among Postmenopausal Women With Osteoporosis and Mild‐to‐Moderate Chronic Kidney Disease
por: Miller, Paul D, et al.
Publicado: (2022)

Effect of Romosozumab on Trabecular Bone Score Compared to Anti-Resorptive Agents in Postmenopausal Women with Osteoporosis
por: Jeong, Chaiho, et al.
Publicado: (2022)

Beneficial effects of switching to denosumab from bisphosphonates or selective estrogen receptor modulators in postmenopausal women with type 2 diabetes and osteopenia/osteoporosis
por: Miyoshi, Arina, et al.
Publicado: (2020)

Effect of denosumab switched from bisphosphonates in preventing joint destruction in postmenopausal rheumatoid arthritis patients with anti-cyclic citrullinated peptide antibodies
por: Mori, Yu, et al.
Publicado: (2021)

Impact of romosozumab on serum calcium concentration and factors predicting the fluctuations in calcium concentration upon romosozumab administration: A multicenter retrospective study
por: Inose, Hiroyuki, et al.
Publicado: (2022)

Intravenous bisphosphonates for postmenopausal osteoporosis
por: Mottaghi, Peyman
Publicado: (2010)

Romosozumab and cardiovascular safety in Japan
por: Takeuchi, Yasuhiro
Publicado: (2021)

Review on the comparison of effectiveness between denosumab and bisphosphonates in post-menopausal osteoporosis
por: Benjamin, Biju, et al.
Publicado: (2016)

Hypercalcaemia after treatment with denosumab in children: bisphosphonates as an option for therapy and prevention?
por: Sydlik, Carmen, et al.
Publicado: (2020)

Denosumab-Induced Rebound Hypercalcemia Treated With Bisphosphonates in a Pediatric Patient
por: Gandolfi, Anne, et al.
Publicado: (2023)

Emerging treatments for postmenopausal osteoporosis – focus on denosumab
por: Geusens, Piet
Publicado: (2009)

Safety and tolerability of denosumab for the treatment of postmenopausal osteoporosis
por: Lewiecki, E Michael
Publicado: (2011)

Denosumab: an investigational drug for the management of postmenopausal osteoporosis
por: Lewiecki, E Michael
Publicado: (2008)

Update on Denosumab Treatment in Postmenopausal Women with Osteoporosis
por: Min, Yong-Ki
Publicado: (2015)

Four-Year Teriparatide Followed by Denosumab vs. Continuous Denosumab in Glucocorticoid-Induced Osteoporosis Patients With Prior Bisphosphonate Treatment
por: Hirooka, Yasuaki, et al.
Publicado: (2021)

Anatomical and Simulation Studies Based on Three-Dimensional-Computed Tomography Image Reconstruction of Femoral Offset
por: Shimizu, Tomohiro, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_rald0580i560f99r7lndkg5tqr